Navigation Links
AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
Date:8/29/2007

CASTLE ROCK, Colo., Aug. 29 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, reported today the company has been invited to present at the annual Roth Capital Partners New York Investor Conference to be held September 5 and 6, 2007. More than 1,200 institutional investors are expected to attend the conference, which will be held at the Westin New York at Times Square.

AspenBio's CEO Richard Donnelly is scheduled to present on Thursday, September 6, at 2:00 P.M. Eastern Time. A simultaneous Webcast will be available at: http://www.wsw.com/webcast/roth13/apnb.ob.

Mr. Donnelly will discuss progress of AspenBio key products, including a specialized assay that detects a marker in the blood associated with appendicitis. According to three studies conducted during the past 33 months, including an ongoing 400 patient study, the company's AppyScore(TM) blood test has been able to identify patients with appendicitis at a very high sensitivity level of 94% to 97%. This compares to significantly lower diagnostic success rates for expensive CT scans, which are generally considered the best diagnostic method currently available for appendicitis. With the AppyScore emergency room triage test and its sister product, AppyScreen(TM), designed for physician offices, AspenBio is targeting a significant need for more economical, accurate and faster assessment of the appendicitis condition.

Roth Capital Partners Stock Conferences are among the largest in the nation for micro and small-cap companies in the technology,
'/>"/>

SOURCE AspenBio Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... YORK , July 27, 2015 ... today announced the winners of its annual Klerman ... research by scientists who have been supported by ... career scientists to pursue innovative ideas in neurobiological ... "proof" of concept for the early detection, treatment, ...
(Date:7/25/2015)... ... ... Technology leader Anton Paar offers the Abbemat T-Check ... of the measuring prism. This is required to achieve the most precise refractive ... requirements. It is likely that no refractometer manufacturers on the market can traceably ...
(Date:7/24/2015)... DIEGO , July 24, 2015 Orexigen ... and financial results for the second quarter 2015 on ... announcement, Orexigen will provide a business update and discuss ... call at 8:00 a.m. Eastern Time (5:00 a.m. Pacific ... by phone by calling (800) 447-0521 (domestic) or (847) ...
(Date:7/23/2015)... , July 23, 2015 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") ... financial results for the second quarter 2015 on Thursday, August ... call and webcast on that day at 5:00 pm ET ... a business update. The call will be hosted by ... , , , LIVE CALL: , , ...
Breaking Biology Technology:Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 2Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 3Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 4Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 5Brain & Behavior Research Foundation Names Winners of Klerman-Freedman Prizes for Exceptional Research 6It’s T-Time for Refractometers: On-site Temperature Check Now Available 2ImmunoCellular Therapeutics to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... , ... CEO, Matthew Sarad, plans a series of experiments to demonstrate the power of nanotechnology ... ... Mr. Matthew Sarad, has announced plans to attempt to rejuvenate living animals with advanced ...
... HORSHAM, Pa., Sept. 10 Centocor Ortho Biotech Products, L.P. ... U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug ... in combination with docetaxel for the treatment of women with ... Centocor Ortho Biotech is evaluating the FDA,s letter and ...
... , ABBOTT PARK, Ill. and MENLO ... announced today a definitive agreement to acquire the outstanding equity of ... minimally invasive repair of cardiac mitral valves. The acquisition provides ... for structural heart disease, in which physicians use catheter-based devices to ...
Cached Biology Technology:Matthew Sarad to Reverse Aging and Cure Cancer 2Matthew Sarad to Reverse Aging and Cure Cancer 3Matthew Sarad to Reverse Aging and Cure Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 2Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 3Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 4Centocor Ortho Biotech Receives FDA Complete Response Letter Regarding DOXIL(R) for the Treatment of Advanced Breast Cancer 5Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 2Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 3Abbott to Acquire Evalve, Inc., a Leader in Minimally Invasive Cardiac Valve Repair Technology 4
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... Systems market, over the next six years. It contains ... affect the industry, along with their impact from the ... It also discusses the industry, market, and technology ... expected that the need of concerned authorities to efficiently ...
(Date:6/24/2015)... 24, 2015 Biometry authentication provider KeyLemon ... password solution one face in. ... one face in, entering the expanding biometric authentication ... multifactor-authentication biometric answer to the password problem. With ... partnership with KeyLemon, one face in allows users ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... Resources, one of the world,s leading research and advisory ... most of the biomarker-drug success stories are in oncology, ... chronic conditions, and their use in clinical trials of ... report entitled Driving Drug and Diagnostic R&D: ...
... 2013 -- Researchers have identified some of the underlying physics ... a stall in midflight -- unlike conventional fixed wing aircraft, ... The analysis, in which the researchers studied the ... how insects fly and informs the design of small flying ...
... 2013 A bicoastal group of scientists at Sanford-Burnham ... grant from the U.S. Department of the Air Force ... chemicals. The goal of the project is to provide ... a rapid, cost-effective manner. "The current approach to ...
Cached Biology News:Use of Biomarkers in Clinical Trials for Drugs Outside of Oncology is Increasing 2Sanford-Burnham receives US Air Force grant to perform next-generation toxicity screens 2
... ChipWriter Pro system, 220-240 V, uses floating ... oligonucleotides, carbohydrates, lipids, and other biomolecules onto ... This system can generate high-density arrays with ... or greater than 57,000 spots per membrane ...
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
The SmartSpec printer paper is used to record data generated by the SmartSpec Plus spectrophotometer. Supplied as 5 packs....
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: